ERBB2 and cancer: Cancer therapies, including hormonal therapies, doxorubicin, HER2-blocking agents, immune checkpoint inhibitors (ICIs), and VEGF inhibitors (VEGFi), can accelerate the progression of CKM syndrome by worsening metabolic, renal, and cardiovascular dysfunction.